{"title":"Utilizing Psychedelics to Enhance Well-Being: A Systematic Review.","authors":"Samuel Thomson, Nikos Thomacos","doi":"10.1080/02791072.2025.2484380","DOIUrl":"10.1080/02791072.2025.2484380","url":null,"abstract":"<p><p>Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4, 2024, including studies published from 1994. After applying the inclusion criteria (controlled or naturalistic experimental design with an outcome measurement at least 7 days post-consumption), 19 studies were included. Encompassing 949 participants, two studies involved 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), seven ayahuasca, two lysergic acid diethylamide (LSD), and eight psilocybin. Results consistently indicate psychedelic consumption is related to enduring enhancements in PERMA's five elements of well-being, including positive emotions, engagement, relationships, meaning, and accomplishment. While discussion of adverse effects was frequently absent, no serious adverse effects were reported in six studies. Future research should address the limitations of the included studies by conducting larger-scale, longitudinal randomized controlled trials that incorporate a comprehensive assessment of well-being. Nevertheless, the findings of this systematic review call for a paradigm shift, moving beyond a disease-focused lens to recognizing psychedelics' capacity to enhance well-being in healthy individuals, ultimately fostering human flourishing.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"653-669"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Construction and Standardization of Perceived Shame Scale for Young Adults with Paternal Substance Use Disorder in Pakistan.","authors":"Muhammad Nasar Iqbal, Shirmeen Ijaz, Zohaib Ahmed, Fatima Javed, Mujahid Iqbal","doi":"10.1080/02791072.2025.2484378","DOIUrl":"10.1080/02791072.2025.2484378","url":null,"abstract":"<p><p>Young adults who struggle with paternal substance use disorder frequently experience elevated levels of shame, which are a result of both internalized feelings of inadequacy and societal stigma. This study aims to develop and validate a perceived shame scale with paternal substance use disorder. This study comprises two phases. Phase I involves the development of the perceived shame of paternal substance use disorder scale, and Phase II aims to validate this scale. This study employed a mixed-method research design and purposive sampling technique was used to collect data from 340 participants for exploratory factor analysis (EFA) and 300 participants for confirmatory factor analysis (CFA). Participants, aged 20-30 years (<i>M = 25.12, SD = 3.05</i>) were recruited. The results finalized twenty-two (22) items with four sub-scales after CFA i.e. psychological problems, interpersonal problems, existential problems, and social problems demonstrating excellent validity and reliability. In conclusion, the results provide a useful tool for future research and clinical interventions aimed at addressing paternal substance use disorder and related emotional difficulties, in addition to furthering our understanding of the internalized and societal causes of shame. The findings of this study have important ramifications for developing empathy, lowering stigma, and advancing efficient support networks for those dealing with this difficult problem.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"899-907"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brant Maclean, Amy Wilson, Andrew Allen, Vikki Schaffer, Lee Kannis-Dymand
{"title":"Ayahuasca Retreats: The Role of Awe and Mystical Experiences in Well-Being.","authors":"Brant Maclean, Amy Wilson, Andrew Allen, Vikki Schaffer, Lee Kannis-Dymand","doi":"10.1080/02791072.2025.2491378","DOIUrl":"10.1080/02791072.2025.2491378","url":null,"abstract":"<p><p>Research on the positive psychological effects of psychedelics has surged since the early 2000s, particularly regarding increased well-being. Studies have demonstrated how psychedelic-occasioned mystical experiences play a key role in their positive effects, which has prompted an interest in the emotion of awe in the psychedelic context due to its similar phenomenology and associated benefits. This study examined 60 individuals following their visitation to at least one ayahuasca retreat in a country where ayahuasca use was legal or retreats are approved to use ayahuasca, hypothesizing that not only high levels of awe but mystical experiences characterized by high levels of awe would be significantly associated with higher well-being. Neither hypothesis was supported: higher levels of mystical experience with lower perceived vastness, a facet of awe, was significantly associated with higher well-being, possibly highlighting the synergistic relationship between mystical experiences and perceived vastness on well-being. The study has implications for future research, particularly in terms of understanding how the perceived vastness of a person's psychedelic experience may be modulated to mitigate distress and foster well-being.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"722-732"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolas G Glynos, Mallet R Reid, Jacob S Aday, Daniel J Kruger, Kevin F Boehnke, Stephanie Lake, Philippe Lucas
{"title":"Racial Differences in Naturalistic Psychedelic Use - Motivations for Use, Communication with Health Care Providers, and Outcomes.","authors":"Nicolas G Glynos, Mallet R Reid, Jacob S Aday, Daniel J Kruger, Kevin F Boehnke, Stephanie Lake, Philippe Lucas","doi":"10.1080/02791072.2025.2491381","DOIUrl":"10.1080/02791072.2025.2491381","url":null,"abstract":"<p><p>People of Color have been under-included in psychedelic-assisted therapy (PAT) research. Researchers have argued that systemic issues resulting in harms to communities of color like the War on Drugs and recurrent exposure to discrimination in healthcare settings may reduce their willingness to engage in PAT research. However, there are no empirical data regarding People of Color's trust or willingness in using psychedelics with support of trained healthcare providers. Therefore, we analyzed data from a large-scale survey of people using psychedelics to explore interactions between People of Color and healthcare providers in North America. The sample included 3,547 White people, 448 People of Color, and 377 Multiracial people. A lower proportion of People of Color consumed psychedelics with the support of a trained provider but an equal proportion had disclosed psychedelic use to primary care providers. Further, People of Color were equally motivated to use psychedelics with a trained healthcare provider, used psychedelics to treat similar issues, and similarly reported psychedelics as effective with other groups. Our findings suggest that lack of trust may not fully explain the underrepresentation of People of Color in PAT research, and future studies should investigate other barriers to People of Color's inclusion in PAT research.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"670-681"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko, Wiesław Jerzy Cubała
{"title":"Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.","authors":"Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko, Wiesław Jerzy Cubała","doi":"10.1080/02791072.2025.2491385","DOIUrl":"10.1080/02791072.2025.2491385","url":null,"abstract":"<p><p>Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy. We extracted data from ClinicalTrials.Gov, EU Clinical Trials (https://euclinicaltrials.eu/), the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/), and the International Clinical Trials Registry Platform (World Health Organization). After rigorous screening and deduplication, we analyzed nine trials. Our findings revealed considerable variability in methodologies, including fixed-dose and ascending-dose designs, diverse inclusion and exclusion criteria, and differing primary and secondary outcomes. Early-phase trials dominate, primarily focusing on pharmacokinetics, withdrawal symptom reduction, and safety monitoring. Key findings indicate significant differences in how safety concerns are addressed, particularly regarding ibogaine's cardiovascular risk. While preliminary evidence suggests potential therapeutic benefits, the absence of large-scale, late-phase trials limits definitive conclusions. Our study underscores the need for a standardized clinical framework to ensure reliable assessments of ibogaine's efficacy and safety. Lessons from research on classical psychedelics, and MDMA could help improve trial design and reduce issues related to blinding and expectancy bias.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"682-692"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study.","authors":"Brandon Biba, Brian A O'Shea","doi":"10.1080/02791072.2025.2511750","DOIUrl":"10.1080/02791072.2025.2511750","url":null,"abstract":"<p><p>New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychedelics and other substances through analyzes of Reddit discussions, using Google's cloud-based Natural Language Processing (NLP) infrastructure. Our findings indicate that illicit substances such as heroin and methamphetamine are associated with highly negative general sentiments, whereas psychedelics like Psilocybin, LSD, and Ayahuasca generally evoke neutral to slightly positive sentiments. This study underscores the effectiveness and cost efficiency of NLP and machine learning models in understanding the public's perception of sensitive topics. The findings indicate that online public sentiment toward psychedelics may be growing in acceptance of their therapeutic potential. However, limitations include potential selection bias from the Reddit sample and challenges in accurately interpreting nuanced language using NLP. Future research should aim to diversify data sources and enhance NLP models to capture the full spectrum of public sentiment toward psychedelics. Our findings support the importance of ongoing research and public education to inform policy decisions and therapeutic applications of psychedelics.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"774-784"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States.","authors":"Joseph J Palamar, Nicole D Fitzgerald","doi":"10.1080/02791072.2025.2570937","DOIUrl":"10.1080/02791072.2025.2570937","url":null,"abstract":"<p><p>The U.S. Drug Enforcement Administration (DEA) proposed a rule in which they intend to place the psychedelic phenethylamines 2,5-dimethoxy-4-chloroamphetamine (DOC) and 2,5-dimethoxy-4-iodoamphetamine (DOI) into Schedule I of the Controlled Substances Act. We investigated the epidemiology of use and availability of these substances. We investigated national trends in seizures of these compounds (which indicate availability) using DEA National Forensic Laboratory Information System (NFLIS) and High Intensity Drug Trafficking Areas (HIDTA) data. We also examined the prevalence of self-reported use on the National Survey of Drug Use and Health (NSDUH), a nationally representative sample of noninstitutionalized individuals aged ≥12 in the United States. The scientific literature was also systematically searched for reports of poisonings linked to use. Between 2005 and 2024, NFLIS received 795 submissions of drugs testing positive for DOC, with a peak of 152 in 2012. There was then a decrease through 2024, with only two submissions containing DOC in 2023-2024. Forty submissions contained DOI, with no submissions testing positive in 2019-2024. Three DOC seizures were recorded by HIDTA in 2017-2021, with none in 2022-2024. HIDTA had no recorded seizures of DOI. Between 2005 and 2023, there were 37 and 10 type-in mentions of lifetime DOC and DOI use, respectively, in NSDUH responses, suggesting a lifetime prevalence of < 0.01% among the noninstitutionalized U.S. population. We located three reports of poisonings linked to DOC use (in 2008-2024) and none linked to DOI use. Availability, recreational use, and poisoning related to the use of DOC and especially DOI appear to be rare.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"922-931"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12645445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145251400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cassidy R LoParco, Carlton Bone, Ashvita Garg, Carla J Berg, Matthew E Rossheim
{"title":"Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.","authors":"Cassidy R LoParco, Carlton Bone, Ashvita Garg, Carla J Berg, Matthew E Rossheim","doi":"10.1080/02791072.2025.2484376","DOIUrl":"10.1080/02791072.2025.2484376","url":null,"abstract":"<p><p>Given the rapid expansion of the derived intoxicating cannabis product (DICPs) market and product diversity, this study assessed marketing information provided by online retailers regarding specific DICP compounds. In May 2023, we searched \"buy delta thc\" in Google's incognito, selected the 20 most trafficked online retailers, and assessed product descriptions and related marketing claims across DICP compounds. 18/20 websites provided descriptions for various DICPs. The top five themes were psychoactive/intoxicating profile (100% of the 18 sites), physical effects (94%), mental effects (94%), naturalness (83%), and safety recommendations (83%). All DICPs, except for THCA and HHC-O, were described as psychoactive/intoxicating; potency was often discussed in relation to delta-9 or delta-8 THC. Claims related to physical effects included improvements to general health, pain management, sleep/insomnia aid (mostly for delta-9 THC). Each compound was described on at least 1 website as having relaxing/calming effects; all compounds except for THCP were described as having anti-anxiety effects. Safety recommendations included buying from trusted/reputable sources; 12 websites mentioned compounds \"suitable for new users\" (deltas-8,9,10 THC, HHC, THCP, THCV). Findings highlight potentially misleading information in DICP marketing and the need for stricter regulatory oversight, as well as required health warnings to protect and educate consumers.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"824-834"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paris Wheeler, B Miller-Roenigk, K Jackson, A Smith, D Stevens-Watkins
{"title":"Cultural Adaptation of Overdose Education Programs: Recommendations from Black Americans with Lived Experience of Opioid and Stimulant Use.","authors":"Paris Wheeler, B Miller-Roenigk, K Jackson, A Smith, D Stevens-Watkins","doi":"10.1080/02791072.2026.2662464","DOIUrl":"10.1080/02791072.2026.2662464","url":null,"abstract":"<p><p>Black Americans have experienced disproportionate overdose deaths due to structural barriers inflicted by systemic racism, particularly among individuals who co-ingest opioids and stimulants. Despite efforts to improve overdose prevention resources on a national level, Black Americans continue to have lower access to naloxone for overdose reversal, are less likely to have received naloxone training, and have lower engagement in other overdose prevention strategies. Community engaged and culturally informed approaches are needed to ensure equitable provision of overdose education and naloxone distribution (OEND). Using empirically supported community engaged methods, the current study centers perspectives of stakeholders with lived experience to identify cultural adaptation needs for OEND programs that specifically target Black adults who use opioids and stimulants. Semi-structured qualitative focus groups revealed several themes that provide insights on cultural adaptation needs, including: centering Black overdose experiences, changes to structure and format, dispelling naloxone myths, coping strategies and alternatives to drug use, motivations for wellness, and sharing with others. Findings can inform more effective dissemination of OEND in Black communities impacted by high overdose rates.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"624-632"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meredith C Meacham, Maha N Mian, Ralph C Wang, Allison R Coker, Brian T Anderson, Juan Carlos C Montoy
{"title":"Latent Classes of Lifetime Use of Seven Hallucinogens in the United States.","authors":"Meredith C Meacham, Maha N Mian, Ralph C Wang, Allison R Coker, Brian T Anderson, Juan Carlos C Montoy","doi":"10.1080/02791072.2025.2537040","DOIUrl":"10.1080/02791072.2025.2537040","url":null,"abstract":"<p><p>Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use and Health (NSDUH) data on a sub-sample of individuals who reported having ever used any hallucinogen (<i>n</i> = 17,977). A four-class model identified the following subgroup classes: <i>Psilocybin</i> (16%), <i>LSD/Psilocybin</i> (46%), <i>Ecstasy</i> (23%), and a fourth class (15%) labeled <i>Multiple substances</i>, with high probabilities of use of psilocybin, LCD, and ecstasy, in addition to moderate probabilities of use of other hallucinogens. In survey-weighted multinomial logistic regression analyses, compared to the <i>Psilocybin</i> class, the adjusted odds of being in the <i>LSD/Psilocybin</i> class increased with age-group level (AORs = 1.5-6.4, 95% CIs:1.3-8.7), and non-White participants had higher odds of being in the <i>Ecstasy</i> class (AORs = 1.7-3.2, 95% CIs:1.1-4.4). As policies regulating and clinical practice with hallucinogens continue to evolve, these patterns of lifetime hallucinogen use demonstrate the overlapping nature of hallucinogen experiences in the U.S. population, which has implications for expanding clinical trial inclusion criteria and establishing a baseline for future trends.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"756-762"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}